Three years of an antibody every two months after a stem cell transplant kept younger people with mantle cell lymphoma in remission longer. A survival advantage seen at four years was no longer statistically significant at seven.
Younger patients with mantle cell lymphoma are treated intensively, with cytarabine-containing induction and an autologous stem-cell transplant, and still relapse. LyMa asked whether rituximab maintenance after the transplant changes that.
299 patients under 66 at diagnosis received four courses of R-DHAP induction, after which the overall response rate was 89 per cent and the complete response rate 77 per cent. 257 were transplanted and 240 were randomised to rituximab 375 mg per square metre every two months for three years, or to observation. At a median follow-up of 50.2 months from randomisation, four-year event-free survival was 79 per cent (95 per cent confidence interval 70 to 86) with rituximab against 61 per cent (51 to 70) with observation (p = 0.001), and four-year progression-free survival 83 per cent (73 to 88) against 64 per cent (55 to 73). Overall survival was also prolonged at four years (89 against 80 per cent, p = 0.04).
With longer follow-up the remission benefit held and the survival one did not: at seven years progression-free survival was 78.5 against 47.4 per cent, and at seven years the overall survival difference was no longer statistically significant (83.2 against 72.2 per cent, hazard ratio 0.63, 95 per cent confidence interval 0.37 to 1.08, p = 0.088) (Journal of Clinical Oncology 2024). It became standard for transplanted patients on the remission benefit. The TRIANGLE trial has since asked whether the transplant itself is still needed when ibrutinib is added to induction and maintenance.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
240 randomised.
95 per cent confidence interval 70 to 86 · 51 to 70
Source73 to 88 · 55 to 73
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Event-free survival at 4 yearsprimary | Rituximab maintenance | 120 | 79% | - | 0.001 | link |
| Observation | 120 | 61% | ||||
| Progression-free survival at 4 years | Rituximab maintenance | 120 | 83% | - | - | - |
| Observation | 120 | 64% |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Steven Le Gouill, Maintenance and consolidation in lymphoma: where it works and where it does not, TRIANGLE, CCND1 and the tag lymphoma-evidence.
Shares Catherine Thieblemont, Maintenance and consolidation in lymphoma: where it works and where it does not, Gilles Salles, Maintenance therapy and the tag lymphoma-evidence.
Shares Steven Le Gouill, Maintenance and consolidation in lymphoma: where it works and where it does not, Gilles Salles, Maintenance therapy and the tag lymphoma-evidence.
Shares Catherine Thieblemont, Maintenance and consolidation in lymphoma: where it works and where it does not, Gilles Salles, Maintenance therapy and the tag lymphoma-evidence.
Shares Maintenance and consolidation in lymphoma: where it works and where it does not, Gilles Salles, Maintenance therapy, CD20 and the tag lymphoma-evidence.
Shares Maintenance and consolidation in lymphoma: where it works and where it does not, Gilles Salles, Maintenance therapy, CD20 and the tag lymphoma-evidence.
Shares TRIANGLE, CCND1, Maintenance therapy, CD20 and the tag lymphoma-evidence.
Shares Autologous stem cell transplant (ASCT), Stem cell transplant in lymphoma: what it is still for, Cytarabine, CD20 and the tag lymphoma-evidence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/